Coto V, Oliviero U, Cocozza M, Lucariello A, Picano T, Coto F, Cacciatore L
Department of Internal Medicine, II Medical School, University of Naples, Italy.
Drugs Exp Clin Res. 1989;15(5):231-4.
The antihypertensive effect of a recently introduced antiserotoninic drug, ketanserin, was examined in a single-blind, placebo-controlled parallel group study in 28 patients with mild to moderate hypertension. Supine and standing blood pressure, electrocardiogram, heart rate and laboratory parameters of liver, kidney and bone marrow functions were checked before and after 3 months of treatment. After 12 weeks' treatment with ketanserin (20-40 mg twice a day), there was a highly significant reduction of both systolic and diastolic blood pressure, as compared to placebo in the supine position (p less than 0.0001/p less than 0.001). In the standing position, the reduction of systolic pressure was more significant than the diastolic pressure (p less than 0.0001/p less than 0.01). Eleven out of 28 hypertensive patients showed electrocardiographic evidence of left ventricular hypertrophy (LVH) according to the ECG criteria of Romhilt and Estes. Although a reduction of the mean point score for LVH as compared to placebo was observed in the ketanserin group, that difference was not statistically significant. These preliminary observations suggest a possible role of ketanserin in the regression of LVH due to essential hypertension.
在一项针对28例轻至中度高血压患者的单盲、安慰剂对照平行组研究中，对最近引入的抗血清素药物酮色林的降压效果进行了检验。在治疗3个月前后，检查了仰卧位和站立位血压、心电图、心率以及肝、肾和骨髓功能的实验室参数。在用酮色林（每日两次，每次20 - 40毫克）治疗12周后，与仰卧位服用安慰剂相比，收缩压和舒张压均显著降低（p小于0.0001/p小于0.001）。在站立位，收缩压的降低比舒张压更显著（p小于0.0001/p小于0.01）。根据Romhilt和Estes的心电图标准，28例高血压患者中有11例显示出左心室肥厚（LVH）的心电图证据。尽管与安慰剂相比，酮色林组LVH的平均积分有所降低，但差异无统计学意义。这些初步观察结果表明，酮色林在原发性高血压所致LVH的消退中可能发挥作用。
